Abstract Library

#1810 FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS

Introduction: Gastro-entero-pancreatic neuroendocrine tumors(GEP-NETs) and metabolic syndrome(MS) are both increasing exponentially. MS has been associated with several non NET cancers.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Pereira R

Authors: Pereira R, Pereira S, Morais T, Costa M, Sampaio P,

Keywords: GEP-NETs, metabolic syndrome, FOXM1, IGF1R, IL-6, Ki67 ,

#1725 Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial

Introduction: Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: pusceddu s

Authors: Prinzi N, Femia D, Concas L, Lo Russo G, Vernieri C,

Keywords: lanreotide, metformin,

#1462 Cross-Talk Between EGFR and IGF1R Influences the Response to RTK Inhibitors in Bronchopulmonary (BP)-NET Cell Lines

Introduction: BP-NETs represent ~30% of all neuroendocrine tumors. BP-NET treatment is challenging due to onset of resistance to chemo and targeted therapies. EGFR and IGF1R had been associated with tumor onset and progression in several neoplasia.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gagliano T

Authors: Gagliano T, Gentilin E, Benfini K, Falletta S, Di Pasquale C,

Keywords: BP-NET RTK,

#1086 mTOR Down-Stream Signaling Pattern May Predict pNET Response to Everolimus

Introduction: NETs are rare neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The mammalian target of rapamycin (mTOR) pathway plays a central role in the regulation of cell growth, metabolism, and apoptosis representing a novel molecular target. This pathway is constitutively activated in pancreatic NETs (pNETs) providing the basis for the development of specific mTOR inhibitors as new therapeutic tools.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Falletta S, Gagliano T, Gentilin E, Di Pasquale C, Benfini K,

Keywords: pNET, Everolimus, mTOR,

#1039 Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET

Introduction: The main treatment for bronchopulmonary NET(BP-NET) is surgery, which is not feasible for infiltrating and metastatic disease, where medical therapy is tried. Identifying new therapeutic targets is important to provide adequate medical treatment for patients with BP-NET. Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI), is mainly described to inhibit VEGF

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Gagliano T

Authors: Gagliano T, Benfini K, Gentilin E, Falletta S, Di Pasquale C,

Keywords: RTK, BP-NET, IGF1R, EGFR,